Biofrontera AG announces initiation of clinical studies
16 nov. 2021 09h01 HE
|
Biofrontera AG
Leverkusen, Germany, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that two...
Biofrontera AG reports completion of the clinical phase of the pharmacokinetics study
08 oct. 2020 11h04 HE
|
Biofrontera AG
Leverkusen, Germany, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, reports the...
Biofrontera Receives Award at Fall Clinical Dermatology Conference 2019
23 oct. 2019 02h00 HE
|
Biofrontera AG
Leverkusen, Germany, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, was presented with...
Biofrontera to present at the Baader Investment Conference
19 sept. 2018 04h03 HE
|
Biofrontera AG
Leverkusen, Germany, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be...